Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Abstral receives marketing approval in Germany for breakthrough cancer pain

Dec. 12, 2008

Perampanel well tolerated in phase II study in patients with refractory partial seizures

Dec. 12, 2008

Olanzapine long-acting injection approved in Europe for schizophrenia

Dec. 12, 2008

Preliminary phase II data suggest APD-125 did not meet trial endpoints

Dec. 12, 2008

AcelRx reports results from phase II clinical study of sufentanil in postoperative pain

Dec. 12, 2008

Phosphagenics presents phase I clinical results for transdermal lidocaine

Dec. 12, 2008

Sosei reports positive results from two phase I trials of SD-118 for neuropathic pain

Dec. 11, 2008

New therapeutic agents for AD and other neurological disorders reported in recent patents

Dec. 11, 2008

Novel analgesic agents reported in recent patent literature

Dec. 11, 2008

AstraZeneca and Targacept present top-line results from phase IIb AZD-3480 trial

Dec. 10, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...